Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.
Resorcylic acid lactones containing a cis-enone are susceptible to Michael addition reactions and are potent inhibitors of several protein kinases. A structural-bioinformatics analysis identified a conserved Cys residue in the ATP-binding site of the kinases reported to be inhibited by cis-enone resorcylic acid lactones but absent in those that are not. Mining of the kinome database revealed that a subset of some 46 kinases contained this Cys residue. Screening a panel of 124 kinases with the resorcylic acid lactone hypothemycin showed that 18 of 19 targets containing the conserved Cys were inhibited. Kinetic analyses showed time-dependent inhibition, a hallmark of covalent inactivation, and biochemical studies of the interaction of extracellular signal-regulated kinase (ERK)2 with hypothemycin confirmed covalent adduct formation. Resorcylic acid lactones are unique among kinase inhibitors in that they target mitogen-activated protein (MAP) kinase pathways at four levels: mitogen receptors, MAP kinase kinase (MEK)1/2 and ERK1/2, and certain downstream ERK substrates. Cell lines dependent on the activation of Tyr kinase mitogen receptor targets of the resorcylic acid lactones were unusually sensitive toward hypothemycin and showed the expected inhibition of kinase phosphorylation due to inhibition of the mitogen receptors and/or MEK1/2 and ERK1/2. Among cells without mitogen receptor targets, those harboring an ERK pathway-activating B-RAF V600E mutation were selectively and potently inhibited by hypothemycin. Hypothemycin also prevented stimulated activation of the p38 cascade through inhibition of the Cys-containing targets MEK3/6 and TGF-beta-activated kinase 1 and of the JNK/SAPK (c-Jun N-terminal kinase/stress-activated protein kinase) cascade through inhibition of MEK4/7.
Schirmer
Andreas
A
Kosan Biosciences, 3832 Bay Center Place, Hayward, CA 94545, USA.
Kennedy
Jonathan
J
Murli
Sumati
S
Reid
Ralph
R
Santi
Daniel V
DV
D000255:Adenosine Triphosphate / Q000378:metabolism; D001665:Binding Sites / Q000235:genetics; D002460:Cell Line; D017124:Conserved Sequence; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D007783:Lactones / Q000494:pharmacology*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D010802:Phylogeny; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011494:Protein Kinases / Q000737:chemistry / Q000145:classification / Q000235:genetics / Q000378:metabolism; D012118:Resorcinols / Q000494:pharmacology*; D013438:Sulfhydryl Compounds / Q000378:metabolism; D015025:Zearalenone / Q000031:analogs & derivatives / Q000494:pharmacology
D007783:Lactones; D047428:Protein Kinase Inhibitors; D012118:Resorcinols; D013438:Sulfhydryl Compounds; C120440:hypothemycin; D015025:Zearalenone; D000255:Adenosine Triphosphate; D011494:Protein Kinases; D019950:Mitogen-Activated Protein Kinase 1